aTyr Pharma, Inc. (ATYR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
aTyr Pharma, Inc. stock (ATYR) is currently trading at $0.79. aTyr Pharma, Inc. PS ratio (Price-to-Sales) is 417.13. Analyst consensus price target for ATYR is $4.36. WallStSmart rates ATYR as Sell.
- ATYR PE ratio analysis and historical PE chart
- ATYR PS ratio (Price-to-Sales) history and trend
- ATYR intrinsic value — DCF, Graham Number, EPV models
- ATYR stock price prediction 2025 2026 2027 2028 2029 2030
- ATYR fair value vs current price
- ATYR insider transactions and insider buying
- Is ATYR undervalued or overvalued?
- aTyr Pharma, Inc. financial analysis — revenue, earnings, cash flow
- ATYR Piotroski F-Score and Altman Z-Score
- ATYR analyst price target and Smart Rating
aTyr Pharma, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
aTyr Pharma, Inc. (ATYR) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
aTyr Pharma, Inc. (ATYR) Key Strengths (2)
Trading at 1.19x book value, attractively priced
55.21% held by institutions, strong professional interest
Supporting Valuation Data
aTyr Pharma, Inc. (ATYR) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 417.1x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
aTyr Pharma, Inc. (ATYR) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.19) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (417.13) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -108.10%, Operating Margin at -40856.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -108.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ATYR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ATYR's Price-to-Sales ratio of 417.13x sits near its historical average of 460.02x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 18% below its historical high of 510.56x set in Feb 2026, and 0% above its historical low of 417.13x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~510.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for aTyr Pharma, Inc. (ATYR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
aTyr Pharma, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 190,000 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 5732% of revenue (11M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact aTyr Pharma, Inc..
Bottom Line
aTyr Pharma, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:23:17 AM
About aTyr Pharma, Inc.(ATYR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.